Compare FA & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FA | ICUI |
|---|---|---|
| Founded | 2003 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 4.0B |
| IPO Year | 2021 | 1995 |
| Metric | FA | ICUI |
|---|---|---|
| Price | $22.25 | $162.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | $26.00 | ★ $193.38 |
| AVG Volume (30 Days) | ★ 1.4M | 184.7K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 72.97 | ★ 100.62 |
| EPS | 0.11 | ★ 1.96 |
| Revenue | $1,574,389,000.00 | ★ $2,231,262,000.00 |
| Revenue This Year | $8.35 | N/A |
| Revenue Next Year | $6.69 | $4.44 |
| P/E Ratio | $196.91 | ★ $83.74 |
| Revenue Growth | ★ 83.02 | N/A |
| 52 Week Low | $8.82 | $113.37 |
| 52 Week High | $25.15 | $192.85 |
| Indicator | FA | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 68.84 | 49.40 |
| Support Level | $19.47 | $151.06 |
| Resistance Level | $22.58 | $167.67 |
| Average True Range (ATR) | 0.83 | 5.18 |
| MACD | 0.29 | 0.27 |
| Stochastic Oscillator | 98.48 | 44.06 |
First Advantage Corp is a provider of software and data in the Human Resources technology industry. The company provides end-to-end identity solutions, criminal background screening, credential verifications, drug and health screening, and continuous risk monitoring. It combines AI-powered proprietary technology platforms with proprietary data, primary source data, and third-party data. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. The company generates maximum revenue from the Sterling segment, which provides similar services as compared to First Advantage's Americas and International segments on a global basis. Geographically, the company generates the majority of its revenue from the United States.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.